{"nctId":"NCT01724528","briefTitle":"Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies","startDateStruct":{"date":"2012-10"},"conditions":["Tumor Lysis Syndrome"],"count":346,"armGroups":[{"label":"Febuxostat","type":"EXPERIMENTAL","interventionNames":["Drug: Febuxostat"]},{"label":"Allopurinol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Allopurinol"]}],"interventions":[{"name":"Febuxostat","otherNames":["Adenuric"]},{"name":"Allopurinol","otherNames":["Zyloric"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients scheduled for first cytotoxic chemotherapy cycle, regardless of the line of treatment, because of hematologic malignancies at intermediate or high risk of TLS (according to the TLS risk stratification, Cairo M et al, British Journal of Haematology, 2010)candidate to Allopurinol treatment or have no access to Rasburicase\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3\n* Life expectancy \\> 1 month\n\nExclusion Criteria:\n\n* Patients known to be hypersensitive to Febuxostat or Allopurinol or to any of the components of the formulations\n* Patients with sUA levels ≥ 10 mg/dL at randomization\n* Patients receiving Febuxostat, Allopurinol or any other urate lowering therapy (e.g. Rasburicase, probenecid) within 30 days prior to randomization\n* Patients with severe renal and/or hepatic insufficiency\n* Patients with diagnosis of LTLS or CTLS at randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serum Uric Acid (sUA) Level Control","description":"Area under the curve of sUA from baseline (Day 1) to the evaluation visit (Day 8)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"514.0","spread":"225.71"},{"groupId":"OG001","value":"708.0","spread":"234.42"}]}]}]},{"type":"PRIMARY","title":"Preservation of Renal Function","description":"Change in serum creatinine level from baseline (Day 1) to the evaluation visit (Day 8)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"26.977"},{"groupId":"OG001","value":"-4.92","spread":"16.695"}]}]}]},{"type":"SECONDARY","title":"Treatment Responder Rate","description":"Assessment of treatment responder rate, where treatment response is defined as the maintenance of sUA ≤ 7.5 mg/dL from Day 3 to Day 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Laboratory Tumor Lysis Syndrome (LTLS)","description":"Assessment of LTLS, from Day 3 to Day 8. According to Cairo-Bishop definition LTLS is defined by the presence of 2 or more laboratory abnormalities including: a 25% increase or levels above normal for serum uric acid, potassium, and phosphate or a 25% decrease or levels below normal for calcium.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Clinical Tumor Lysis Syndrome (CTLS)","description":"Assessment of CTLS, from Day 3 to Day 8. According to Cairo-Bishop definition, CTLS is defined by the presence of LTLS in addition to 1 or more of the following significant clinical complications: renal insufficiency, cardiac arrhythmias, sudden death and seizures. The grade of CTLS is defined by the maximal grade of the clinical manifestation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Treatment Emergent Signs or Symptoms (TESS)","description":"Incidence, severity, seriousness and treatment-causality of TESS","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":173},"commonTop":["Neutropenia","Anaemia","Leukopenia","Thrombocytopenia","Nausea"]}}}